Supernus Pharmaceuticals Inc. (SUPN)

The total asset value of Supernus Pharmaceuticals Inc. (SUPN) stood at $ 2,523 Mln as on 31-Mar-23

The share price of Supernus Pharmaceuticals Inc. (SUPN) is $28.11 (NASDAQ) as of 04-Dec-2023 16:00 EST. Supernus Pharmaceuticals Inc. (SUPN) has given a return of 8.91% in the last 3 years.

Supernus Pharmaceuticals Inc. (SUPN) has a market capitalisation of $ 1,827 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

The P/B ratio of Supernus Pharmaceuticals Inc. (SUPN) is 2.23 times as on 02-Jun-2023, a -0.21% premium to its peers’ median range of 2.82 times.

The P/E ratio of Supernus Pharmaceuticals Inc. (SUPN) is 37.26 times as on 02-Jun-2023, a 0.71% premium to its peers’ median range of 21.83 times.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Supernus Pharmaceuticals Inc. (SUPN) and enter the required number of quantities and click on buy to purchase the shares of Supernus Pharmaceuticals Inc. (SUPN).

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

The CEO & director of Mr. Jack A. Khattar. is Supernus Pharmaceuticals Inc. (SUPN), and CFO & Sr. VP is Mr. Timothy C. Dec.

The promoters of Supernus Pharmaceuticals Inc. (SUPN) have pledged 0% of the total equity as on Dec-22.

Some of the close peers are:

Yes, TTM profit after tax of Supernus Pharmaceuticals Inc. (SUPN) was $52 Mln.